Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated

TargetMol | SPR
Catalog No. TMPK-00492 Copy Product Info
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.

IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated

Catalog No. TMPK-00492
Copy Product Info
TargetMol | SPR

Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.

IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated
Pack SizePriceUSA StockGlobal StockQuantity
5 μg$917-10 days7-10 days
10 μg$1487-10 days7-10 days
20 μg$2457-10 days7-10 days
50 μg$4837-10 days7-10 days
100 μg$8137-10 days7-10 days
200 μg$1,4707-10 days7-10 days
500 μg$3,2507-10 days7-10 days
Add to Cart
Add to Quotation
For In stock only · Estimated delivery:USA Stock (1-2 days) Global Stock (5-7 days)
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
View More

Batch Information

Product Information

Biological Activity
Biotinylated Cynomolgus IL-18BP, His tag captured on CM5 Chip via anti-his antibody can bind Human IL-18, No Tag with an affinity constant of 1.67 nM as determined in SPR assay.
Description
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.
Species
Cynomolgus
Expression System
HEK293 Cells
TagC-His
Accession NumberA0A2K5UDJ4
Synonyms
Interleukin-18-binding protein,IL-18BP,Igifbp
Construction
Thr28-Pro207
Protein Purity
> 95% as determined by Tris-Bis PAGE; > 90% as determined by HPLC
Molecular Weight21.14 kDa (predicted). Due to glycosylation, the protein migrates to 50-65 kDa based on Tris-Bis PAGE result.
Endotoxin< 1.0 EU/μg of the protein as determined by the LAL method.
FormulationSupplied as 0.22 μm filtered solution in PBS (pH 7.4).
Stability & Storage
It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots.
ShippingProteins are shipped with blue ice.
Research Background
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.

Dose Conversion

You can also refer to dose conversion for different animals. More

Calculator

  • Reconstitution Calculator
  • Recombinant Protein Dilution Calculator
  • Specific Activity Calculator

Tech Support

Please read the User Guide of Recombinant Proteins for more specific information.